PACB News and Press, Pacific Biosciences of California Inc. From 10/25/22

PacBio Announces Revio, a Revolutionary New Long Read Sequencing System Designed to Provide 15 Times More HiFi Data and Human Genomes at Scale for Under $1,000 PR Newswire Significant Advances in SMRT Cell Design, Compute, and a New System Architecture Will Enable Revi...

PacBio Announces Onso, the Highly Accurate Short-Read Sequencing Platform PR Newswire The Onso Sequencing System is Designed to Deliver Industry-Leading Sensitivity and Specificity for Novel Insights in Oncology and Disease Research MENLO PARK, Calif. , ...

PacBio to Report Third Quarter Earnings on November 7 and Host Inaugural Investor Day on November 15 PR Newswire Withdraws Guidance with New Product Announcement MENLO PARK, Calif. , Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced to...

PacBio Launches Single-Cell Transcriptome Solution Ushering in a New Era of RNA Discovery PR Newswire MAS-Seq Supports Isoform Research Using Single-Cell RNA Sequencing from 10x Genomics MENLO PARK, Calif. , Oct. 20, 2022 /PRNewswire/ -- PacBio ...

PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing PR Newswire Alliance panels include a 50-gene pharmacogenomics panel and a nearly 400-gene panel of challenging, medically relevant "dark genes" developed in collabora...

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...

PacBio Collaborates with Leading Researchers to Establish Long-Read Variant Frequency Consortium PR Newswire The Consortium Will Build a Publicly Available Database as a Resource to Accelerate Insights from Long-Read Human Genome Datasets MENLO PARK, Calif. ...

Summary There is a high chance that the Illumina, Inc.-Grail deal would collapse after European regulators decide to block the acquisition. Without Grail, I believe Illumina will find it hard to maintain growth in light of disruptions in its end markets, namely the clinical gene t...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

PacBio Unveils a New Method for Comprehensive, Genome-wide Tandem Repeat Analysis PR Newswire Analysis Method Supports Research on the Genetic Causes of Common Diseases MENLO PARK, Calif. , Sept. 27, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB),...